Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present InVivo Therapeutics Holdings Corp (NASDAQ: NVIV).

Full DD Report for NVIV

You must become a subscriber to view this report.


Recent News from (NASDAQ: NVIV)

InVivo Therapeutics up 8% on collaborating with privately held Q Therapeutics
InVivo Therapeutics (NASDAQ: NVIV ) has entered into a joint research agreement with Q Therapeutics, a privately held developer of clinical-stage cell therapies for central nervous system (CNS) disease and injury. More news on: InVivo Therapeutics Holdings Corp, Healthcare stocks news, S...
Source: SeekingAlpha
Date: October, 02 2018 08:24
InVivo Therapeutics Announces Joint Research Collaboration with Q Therapeutics, Inc.
- Aims to evaluate the preclinical safety and feasibility of the Neuro-Spinal Scaffold™ with stem cells - InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries ...
Source: Business Wire
Date: October, 02 2018 08:00
InVivo Therapeutics Announces Publication of Neuro-Spinal Scaffold Preclinical Data in Peer-Reviewed Journal Biomaterials
- Supports INSPIRE clinical investigation of the Neuro-Spinal Scaffold - InVivo Therapeutics Holdings Corp. (Nasdaq:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries (SCIs), today announced the publication o...
Source: Business Wire
Date: October, 01 2018 08:00
InVivo Therapeutics Announces Presentation at the Ladenburg Thalmann 2018 Healthcare Conference and Provides Business Update
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at 9:30 am Eastern Time at the Sofitel Hotel in New York, New Y...
Source: Business Wire
Date: September, 28 2018 08:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-121.98992.012.011.9629,676
2018-12-112.001.982.001.892846,032
2018-12-102.011.98992.021.9231,907
2018-12-072.002.032.062.0036,051
2018-12-062.002.052.051.964258,275

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-125,10720,59224.8009Cover
2018-12-1114,13919,07074.1426Short
2018-12-103,43312,42527.6298Cover
2018-12-076,74519,99933.7267Cover
2018-12-063,1526,72946.8420Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NVIV.


About InVivo Therapeutics Holdings Corp (NASDAQ: NVIV)

Logo for InVivo Therapeutics Holdings Corp (NASDAQ: NVIV)

InVivo Therapeutics Holdings Corp. is a pioneering biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in with proprietary technology co invented by Robert Langer, ScD., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In the Company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA.

 

 

 

Current Management

  • Mark Perrin / CEO
  • Steven F. McAllister / CFO
  • Tamara Joseph / Senior VP, General Counsel
  • Thomas Ulich / CSO
  • Louis Vaickus / Chief Med. Officer
  • Brian Luque / Business Development, IR
  • Daniel R Marshak /

Current Share Structure

  • Market Cap: $23,060,746 - 03/21/2018
  • Issue and Outstanding: 38,054,036 - 03/09/2018

 


Recent Filings from (NASDAQ: NVIV)

Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: May, 17 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 07 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: May, 07 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 07 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: May, 07 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
General form for registration of securities under the Securities Act of 1933
Filing Type: S-1Filing Source: edgar
Filing Date: April, 24 2018
General form for registration of securities under the Securities Act of 1933
Filing Type: S-1Filing Source: edgar
Filing Date: April, 24 2018

 

 


Daily Technical Chart for (NASDAQ: NVIV)

Daily Technical Chart for (NASDAQ: NVIV)


Stay tuned for daily updates and more on (NASDAQ: NVIV)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: NVIV)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NVIV is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of NVIV and does not buy, sell, or trade any shares of NVIV. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/